Liposomal Glutathione
Free oral L-Glutathione has a bioavailability below 1%, as it is hydrolysed by γ-glutamyl transpeptidase and intestinal peptidases before it reaches the circulation. Gastric oxidation simultaneously destroys the thiol group responsible for all antioxidant activity. Lipoedge resolves this with pharmaceutical-grade liposomal glutathione, which shields the intact tripeptide from digestion and delivers it directly into cells via membrane fusion.
- Nano-liposomal particle size: Mean size of ~158.7 nm, confirmed by dynamic light scattering, optimised for intestinal membrane interaction and cellular uptake.
- pH-resilient colloidal stability: Zeta potential of –58.21 mV prevents vesicle aggregation across acidic gastric and intestinal pH conditions throughout shelf life.
- Controlled particle distribution: PDI of ~0.27 confirms a tightly uniform liposome population, ensuring predictable absorption and reproducible formulation performance.
- High glutathione entrapment: Encapsulation efficiency of 91.61% locks the intact tripeptide within the bilayer, protecting the thiol group from oxidation and premature gastric release.
- Simulated gastrointestinal stability: Liposomal matrix shields the GSH tripeptide through gastric pH 1.5 conditions, where free glutathione is fully degraded by GGT and mucosal peptidases.
- GSH release profile: Intestinal fluid triggers controlled release across an extended window, providing continuous intracellular replenishment rather than the rapid clearance of precursor strategies.
- Cellular uptake (Caco-2 model): Phospholipid membrane fusion deposits intact reduced glutathione directly into the cytosol, achieving intracellular concentrations unattainable with free GSH at equivalent doses.
- Thiol group integrity post-delivery: FTIR confirms the –SH stretching vibration is fully preserved through encapsulation and release, validating biologically active delivery at the target site.
- Immune cell loading: Clinical liposomal GSH studies at 500–1000 mg/day confirm elevated GSH levels in whole blood, erythrocytes, plasma, PBMCs, and lymphocytes within 4 weeks.
- Oxidative stress reduction: Plasma oxidative stress markers decline measurably as blood glutathione stores rise, confirming bioactive intracellular delivery at therapeutically relevant concentrations.
Liposomal Glutathione is available in a wide range of dosage formats suitable for both pharmaceutical and nutraceutical applications, offering flexibility for custom formulations.
| Attribute | Traditional Glutathione | Liposomal Glutathione |
|---|---|---|
| Oral Bioavailability | Below 1%; hydrolysed by GGT and intestinal peptidases | Intact tripeptide delivered via phospholipid membrane fusion |
| Thiol Group Integrity | Oxidised in the gastric environment before absorption | –SH group preserved; FTIR-verified post-encapsulation |
| GI Enzymatic Stability | Degraded by pepsin, trypsin, and chymotrypsin in transit | Protected within a bilayer through the full gastric and intestinal phases |
| Sensory Profile | Strong sulfurous odour and taste limit formulation use | The phospholipid matrix effectively masks odour and taste |
| Immune Cell Loading | Negligible lymphocyte and NK cell GSH elevation | Confirmed elevation in PBMCs, erythrocytes, and immune compartments |
| Target Segment | Basic wellness, precursor-based supplement formats | Pharma adjunct, clinical nutraceuticals, premium cosmeceuticals |
- Bypasses enzymatic degradation: The phospholipid bilayer shields the tripeptide from hydrolysis by GGT, pepsin, trypsin, and all intestinal mucosal peptidases through the full GI transit.
- Direct intracellular delivery of intact GSH: Liposomes fuse with cell membranes to deposit intact reduced glutathione directly into the cytosol for immediate antioxidant and detoxification activity.
- Sustained controlled release: Controlled-release kinetics maintain the GSH: GSSG redox ratio throughout the dosing interval, unlike the rapid clearance of NAC or free amino acid precursors.
- Superior odour and taste masking: The phospholipid matrix effectively masks glutathione’s characteristic sulfurous sensory profile, enabling liquid shots, syrups, and flavoured formats previously incompatible with free GSH powder.
- Confirmed immune compartment loading: Liposomal GSH elevates glutathione specifically within lymphocytes and NK cells, where free oral glutathione consistently fails to deliver therapeutically relevant concentrations.
- Multi-format compatibility: Available as water-dispersible powder or granular powder, compatible with capsules, tablets, stick packs, liquid shots, and topical cosmeceutical emulsions across platforms.
Lipoedge Liposomal Glutathione meets WHO-GMP and ISO standards for pharmaceutical-grade B2B manufacturing supply.
| Key Quality Parameter | Formulation Advantage |
|---|---|
| Encapsulation Efficiency (91.61%) | Highest-tier entrapment ensures maximum payload protection from oxidation and enzymatic breakdown |
| Superior Morphology | SEM confirms smooth spherical vesicles transformed from irregular API crystals |
| Thiol Integrity (FTIR-Verified) | –SH stretching confirmed intact; GSH antioxidant potency fully preserved post-encapsulation |
| Stability (40°C/75% RH) | Assay declines only from ~54.12% to ~53.60% over six months of accelerated testing |
| Low Moisture (LOD ~2.14%) | Non-hygroscopic powder matrix; well within the 5.0% specification limit |
Lipoedge Liposomal Glutathione addresses applications where the negligible oral bioavailability of free GSH has historically blocked therapeutic outcomes across hepatic, neurological, immune, and dermal targets.
- Hepatoprotection and liver detoxification: Liposomal delivery achieves intracellular GSH concentrations in hepatocytes, supporting Phase II detoxification and NAFLD, NASH, and drug-induced liver stress adjunct protocols.
- Neurological and cognitive support: Liposomal GSH supports BBB-relevant concentrations for neuroprotection formulations targeting cognitive decline, neuroinflammation, and Parkinson’s disease adjunct applications.
- Immune modulation therapy: Confirmed NK cell and lymphocyte elevation in clinical studies supports immune-compromised patients and oncology supportive care formulation protocols requiring intracellular GSH delivery.
- Premium longevity and cellular health: Liposomal delivery provides confirmed blood and tissue GSH elevation that precursor-only strategies like NAC cannot directly guarantee at the intracellular level.
- Daily antioxidant defence: Capsules, tablets, and stick packs benefit from confirmed intracellular GSH delivery and sustained GSH: GSSG ratio management that free glutathione powder consistently fails to provide.
- Sensory-friendly liquid formats: Effective odour and taste masking opens premium shots, syrups, and functional beverages to glutathione formats where standard free GSH powder is organoleptically incompatible.
- Systemic skin brightening: Liposomal delivery achieves the intracellular GSH concentrations required for tyrosinase inhibition and melanin regulation at the melanocyte level, clinically documented at 250–500 mg per day.
- Anti-ageing and cellular repair: Intact GSH reaches dermal fibroblasts and keratinocytes to support collagen synthesis, reduce free radical-induced protein cross-linking, and drive Phase II detoxification of pro-ageing oxidative metabolites.
- Topical and transdermal delivery: The phospholipid matrix mirrors the skin’s natural lipid bilayer, enabling transdermal GSH delivery in serums, creams, and cosmeceutical emulsions for targeted antioxidant and brightening applications.
Free GSH is hydrolysed by GGT and intestinal peptidases before reaching the mucosa, resulting in bioavailability below 1% regardless of the dose administered. Liposomal encapsulation protects the intact tripeptide throughout full GI transit, enabling direct membrane-mediated cellular delivery.
A four-week clinical study confirmed elevated GSH in whole blood, erythrocytes, plasma, and PBMCs, alongside measurable increases in NK cell and lymphocyte proliferation. Plasma oxidative stress markers declined significantly, validating intracellular bioactive delivery at clinically meaningful concentrations.
Full characterisation, including FTIR, SEM, DLS, DSC, TGA, and HPLC batch Certificates of Analysis, is provided with every supply. WHO-GMP compliance documentation, including support for FSSAI, EU Novel Food, and US NDI notifications, is available upon request.
NAC provides cysteine for endogenous GSH synthesis but cannot guarantee intracellular GSH outcomes in depleted or compromised cellular environments. Lipoedge delivers intact reduced GSH directly to the cytosol, bypassing the need for synthesis and providing immediate antioxidant availability.
Yes, the phospholipid matrix effectively masks glutathione’s sulfurous odour and taste, enabling use in premium shots, syrups, and functional beverages. Standard free GSH powder is organoleptically incompatible with these liquid formats at effective doses.
Non-GMO sunflower or soy phospholipids are used with no animal-derived excipients, synthetic solvent residues, or allergens present in the formulation. Available as vegan-compatible powder and granular powder for clean-label applications across all supplement and functional food formats.
